5 days ago
York firm raises £2 million to fuel growth
York-based life sciences company, Aptamer Group, has raised £2million from a placing of shares.
Aptamer is a leading innovator in developing its Optimer® binder technology, which is being developed for a range of medical treatments.
In the past year, the company reports strong commercial progress, winning a range of fee-for-service contracts.
It has also extended its intellectual property portfolio. Several of these assets have progressed towards licensing, notably a swine vaccine and an Alzheimer's diagnostic, both of which are advancing to licensing agreements.
RECOMMENDED READING:
Aptamer Group reports progress on Fibrosis research
Unilever signs up with Aptamer on body odour product trials
Aptamer Group releases latest interim half yearly results
Aptamer also reports further progress with its Optimer® delivery platform, being used for liver treatments.
The share placing will enable Aptamer to accelerate the commercialisation of its Optimer® technology, further develop its intellectual property portfolio, and advance its licensing pipeline.
The extra cash will also support ongoing R&D, expand fee-for-service capabilities, and strengthen the Company's position as a leader in the global aptamer market, driving long-term value creation for shareholders, it said.
